FORA Capital LLC Has $4.14 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

FORA Capital LLC lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,314 shares of the medical equipment provider’s stock after purchasing an additional 2,371 shares during the period. FORA Capital LLC’s holdings in Zimmer Biomet were worth $4,136,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ZBH. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet in the 3rd quarter valued at $28,000. Bangor Savings Bank bought a new position in Zimmer Biomet in the third quarter valued at about $31,000. Family Firm Inc. acquired a new stake in Zimmer Biomet in the second quarter worth about $33,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet in the third quarter worth about $35,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Zimmer Biomet during the 2nd quarter worth about $43,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 0.6 %

Shares of Zimmer Biomet stock traded up $0.69 on Wednesday, hitting $111.33. The company had a trading volume of 68,952 shares, compared to its average volume of 1,494,042. Zimmer Biomet Holdings, Inc. has a twelve month low of $101.47 and a twelve month high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The stock has a 50-day moving average of $106.95 and a 200-day moving average of $109.47. The firm has a market capitalization of $22.16 billion, a P/E ratio of 21.03, a P/E/G ratio of 2.04 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same period in the prior year, the business earned $1.65 EPS. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date was Monday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ZBH. Oppenheimer reduced their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. Truist Financial lifted their target price on shares of Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a report on Friday, November 1st. Royal Bank of Canada upped their target price on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, November 4th. Wells Fargo & Company raised their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, TD Cowen dropped their price objective on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $123.22.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.